NetworkNewsBreaks – Multiverse Investment Fund’s Orbsen Therapeutics to Initiate Clinical Trials to Treat ARDS Caused by COVID-19
Addressing the finding that most COVID-19 fatalities are caused by the nonreversible development of acute respiratory distress syndrome (“ARDS”), Multiverse Investment Fund today announced that one of its 12 portfolio companies, Orbsen Therapeutics, was awarded a special dispensation by the government of England to initiate clinical trials of its proprietary cellular therapy, ORBCEL, to treat ARDS patients diagnosed with COVID-19. Jack Kavanaugh, a general manager of Multiverse Investment Fund, a private venture capital fund dedicated to long-term capital investment in companies offering significant social impact, and chairman of Orbsen Therapeutics, stated, “We are incredibly proud of Orbsen’s achievements and the…







